KalVista Pharmaceuticals ...

9.19
-0.43 (-4.47%)
At close: Feb 07, 2025, 3:59 PM
9.20
0.11%
After-hours Feb 07, 2025, 04:00 PM EST
undefined%
Bid 8.71
Market Cap 454.15M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -3.68
PE Ratio (ttm) -2.5
Forward PE n/a
Analyst Buy
Ask 9.7
Volume 256,513
Avg. Volume (20D) 374,013
Open 9.58
Previous Close 9.62
Day's Range 9.14 - 9.68
52-Week Range 7.30 - 16.88
Beta undefined

About KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed ...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 9, 2015
Employees 150
Stock Exchange NASDAQ
Ticker Symbol KALV

Analyst Forecast

According to 7 analyst ratings, the average rating for KALV stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 172.03% from the latest price.

Buy 85.71%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 months ago
+8.28%
KalVista Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription
3 months ago
+9.61%
KalVista Pharmaceuticals shares are trading higher. The company announced a share offering and private placement.